1. Home
  2. EDSA vs ABP Comparison

EDSA vs ABP Comparison

Compare EDSA & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • ABP
  • Stock Information
  • Founded
  • EDSA 2015
  • ABP 2004
  • Country
  • EDSA Canada
  • ABP United States
  • Employees
  • EDSA N/A
  • ABP N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • ABP Biotechnology: Pharmaceutical Preparations
  • Sector
  • EDSA Health Care
  • ABP Health Care
  • Exchange
  • EDSA Nasdaq
  • ABP Nasdaq
  • Market Cap
  • EDSA 18.6M
  • ABP 15.2M
  • IPO Year
  • EDSA N/A
  • ABP N/A
  • Fundamental
  • Price
  • EDSA $2.66
  • ABP $0.20
  • Analyst Decision
  • EDSA Strong Buy
  • ABP Hold
  • Analyst Count
  • EDSA 2
  • ABP 1
  • Target Price
  • EDSA $13.00
  • ABP N/A
  • AVG Volume (30 Days)
  • EDSA 140.8K
  • ABP 5.3M
  • Earning Date
  • EDSA 12-12-2025
  • ABP 11-18-2025
  • Dividend Yield
  • EDSA N/A
  • ABP N/A
  • EPS Growth
  • EDSA N/A
  • ABP N/A
  • EPS
  • EDSA N/A
  • ABP N/A
  • Revenue
  • EDSA N/A
  • ABP $183,000.00
  • Revenue This Year
  • EDSA N/A
  • ABP N/A
  • Revenue Next Year
  • EDSA N/A
  • ABP N/A
  • P/E Ratio
  • EDSA N/A
  • ABP N/A
  • Revenue Growth
  • EDSA N/A
  • ABP 154.17
  • 52 Week Low
  • EDSA $1.55
  • ABP $0.15
  • 52 Week High
  • EDSA $4.49
  • ABP $11.19
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 54.92
  • ABP 47.60
  • Support Level
  • EDSA $2.42
  • ABP $0.18
  • Resistance Level
  • EDSA $2.95
  • ABP $0.21
  • Average True Range (ATR)
  • EDSA 0.21
  • ABP 0.02
  • MACD
  • EDSA 0.01
  • ABP 0.00
  • Stochastic Oscillator
  • EDSA 49.86
  • ABP 50.09

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About ABP Abpro Holdings Inc Common Stock

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Share on Social Networks: